Etanercept therapy for psoriatic arthritis in the presence of recurrent nonyhodgkin lymphoma

Journal of Clinical Rheumatology

Volumn 18, Issue 6, 2012, Pages 301-303

  Pai, Sneha ^a   Rosenstein, Elliot D ^b   Kramer, Neil ^b  

^a Department of Medicine   (United States)

^b Overlook Medical Center   (United States)

Author keywords

Etanercept; Lymphoma risk; Psoriasis; Psoriatic arthritis; TNF inhibitors

Indexed keywords

CORTICOSTEROID; ETANERCEPT; FLUDARABINE; LEFLUNOMIDE; METHOTREXATE; RITUXIMAB; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CANCER REGRESSION; CASE REPORT; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; MALE; NAUSEA; NONHODGKIN LYMPHOMA; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RECURRENCE RISK; TREATMENT RESPONSE; TUMOR RECURRENCE;

ARTHRITIS, PSORIATIC; COMBINED MODALITY THERAPY; FATAL OUTCOME; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84868235841     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0b013e3182685515     Document Type: Article

References (16)

1. Margolis D, Bilker W, Hennessy S, et al. The risk of malignancy associated with psoriasis. Arch Dermatol. 2001;137:778-783. (Pubitemid 32577862)
2. Gelfand JM, Shin DB, Neimann AL, et al. The risk of lymphoma in patients with psoriasis. J Invest Dermatol. 2006;126:2194-2201. (Pubitemid 44413165)
3. Mariette X, Tubach F, Bagheri H, et al. Lymphoma in patients treated with anti-TNF: Results of the 3-year prospective French RATIO registry. Ann Rheum Dis. 2010;69:400-408.
4. Baran-Marszak F, Laguillier C, Youlyouz I, et al. Effect of tumor necrosis factor alpha and infliximab on apoptosis of B lymphocytes infected or not with Epstein-Barr virus. Cytokine. 2006;33:337-345. (Pubitemid 43816308)
5. Geborek P, Bladstrom A, Turesson C, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis. 2005;64:699-703. (Pubitemid 40559295)
6. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: The effect of methotrexate and antiYtumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004;50:1740-1751. (Pubitemid 38725085)
7. Askling J, Baecklund E, Granath F, et al. AntiYtumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: Relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis. 2009;68:648-653.
8. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: A network meta-Analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;16:CD008794.
9. Papp KA, Poulin Y, BissonnetteR, . Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol. 2012;66:e33Ye45.
10. Dommasch ED, Abuabara K, Shin DB, et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-Analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64:1035-1049.
11. Kerensky TA, Gottlieb AB, Yaniv S, et al. Etanercept: Efficacy and safety for approved indications. Expert Opin Drug Saf. 2012;11:121-139.
12. Burmester GR, Mease P, Dijkmans BAC, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis. 2009;68:1863-1869.
13. Chong BF,Wong HK. Treatment of psoriasis with etanercept in a patient with a history of primary B-cell lymphoma. Clin Exp Dermatol. 2009;34:e11Ye13.
14. Mielke F, Schneider-Obermeyer J, Dorner T. Onset of psoriasis with psoriatic arthropathy during rituximab treatment of nonYHodgkin lymphoma. Ann Rheum Dis. 2008;67:1056-1057. (Pubitemid 351956683)
15. Brauchli YB, Jick SS, Miret M, et al. Psoriasis and risk of incident cancer: An inception cohort study with a nested case-control analysis. J Invest Dermatol. 2009;129:2604-2612.
16. Dreyer L, Mellemkjaer L, Hetland ML. Cancer in arthritis patients after antiYtumour necrosis factor therapy. Ugeskr Laeger. 2009;171:506-511.